NCT07035340

Brief Summary

Patients who are followed up in the cardiology clinic with a diagnosis of CHF, who have had a CRT implant at least 1 year ago, and who do not receive cardiac rehabilitation will be included. The aim of the study is to investigate the effects of inspiratory muscle training (IMT) on exercise capacity, respiratory muscle strength, NTproBNP and quality of life. Groups Intervention group: Treatment with IMT Control group: Standard care Study hypothesis;

  1. 1.Does IMT have an effect on exercise capacity and quality of life in patients with CRT?
  2. 2.Does IMT have an effect on NTproBNP in patients with CRT?

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 15, 2024

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

June 13, 2025

Completed
2 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 15, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 15, 2025

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 25, 2025

Completed
Last Updated

July 18, 2025

Status Verified

June 1, 2025

Enrollment Period

1.1 years

First QC Date

June 13, 2025

Last Update Submit

July 17, 2025

Conditions

Keywords

inspiratory muscle trainingcardiac resynchronization therapyexercises capacityquality of life

Outcome Measures

Primary Outcomes (4)

  • NT-proBNP

    NT-proBNP

    enrollment and end of the 12 week treatment

  • Exercises capacity

    Exercise capacity was evaluated using the 6-minute walk test (6MWT). 6MWT was performed according to the ATS/ERS criteria.

    enrollment and end of the first week of treatment

  • Heart rate (Exercises capacity)

    Heart rate were measured using a portable pulse oximeter (Cosmed Srl, Cosmed Spiropalm, Rome, Italy), before, after and 1 minute recovery.

    enrollment and end of the first week of treatment

  • Quality of Life of patients

    Qality of life was assessed using the Nottingham Health Profile (NHP) self-reported tool. The NHP questionnaire evaluates six dimensions of health (pain, energy level, sleep, physical abilities, emotional reaction and social isolation) and includes 38 items. Total NHP score ranges between 0-600 and quality of life perception is negatively associated with score received

    enrollment and end of the 12 week treatment

Secondary Outcomes (2)

  • Respiratory muscle strength

    enrollment and end of the first week of treatment

  • The performance of patients' activities of daily living

    at enrollment and end of the 12 week treatment

Study Arms (2)

İntervention group

EXPERIMENTAL

inspiratory muscle training

Other: inspiratory muscle training

Control group

OTHER

Standart care

Other: standart care

Interventions

inspiratory muscle traning MIP%40-60

İntervention group

standart care

Control group

Eligibility Criteria

Age45 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who were followed up in the cardiology clinic with a diagnosis of CHF,
  • CRT implanted at least 1 year ago,
  • did not receive cardiac rehabilitation,
  • years old,
  • communicate in Turkish,
  • NYHA II-III

You may not qualify if:

  • orthopedic and neurological disorders that may prevent walking,
  • acute respiratory tract infection in the last month,
  • NYHA I were not included in this study because they were generally not hospitalised and the problems were managed with outpatient diagnosis and treatment, and patients with class IV were not included in this study because they showed severe symptoms for medical and ethical reasons and they were not wanted to be forced with this long-lasting survey application process.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tarsus University

Mersin, Mersin, Turkey (Türkiye)

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
Doctor who doing ekogardiography.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Phd,PT

Study Record Dates

First Submitted

June 13, 2025

First Posted

June 25, 2025

Study Start

May 15, 2024

Primary Completion

June 15, 2025

Study Completion

June 15, 2025

Last Updated

July 18, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations